Cellectar Biosciences INC NEW
CLRBCellectar Biosciences, Inc. is a biotechnology company focused on the development of targeted cancer therapies using its proprietary phospholipid drug platform. The company specializes in creating novel compounds that deliver therapeutic agents directly to cancer cells, aiming to improve efficacy and reduce side effects. Cellectar's pipeline includes treatments for various oncology indications, leveraging its expertise in phospholipid chemistry and drug delivery technologies.
Company News
The Waldenstrom macroglobulinemia market is experiencing steady growth driven by advances in targeted therapies, particularly BTK inhibitors. Rising awareness, improved diagnostics, and increasing clinical trials are propelling market expansion, with several emerging drugs showing promise in treating this rare lymphoma.
Cellectar Biosciences, Inc. announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing restated financial statements for 2022, 2023, and the first half of 2024.
Cellectar Biosciences, Inc. announced that it needs to restate its previously issued financial statements due to a review of its accounting treatment for warrants issued in a 2022 financing. The company has received a delinquency notification from Nasdaq and has 60 days to submit a plan to regain compliance.
Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT Event scheduled for Wednesday, July 24, 2024, at 8:00 am EDT
Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma
